enGene
Social media
enGene Logo
About enGene
enGene Holdings Inc. is a clinical-stage biotechnology company specializing in the development of genetic medicines for the treatment of serious diseases. The company focuses on drug development and commercialization in oncology, with its lead product candidate, detalimogene voraplasmid, being a non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC) in patients unresponsive to Bacillus Calmette-Guérin (BCG). enGene leverages its proprietary gene delivery platform to enable localized delivery of gene therapies, aiming to address unmet medical needs in the United States and Canada.
Address
4868 Rue Levy, Suite 220
Montreal, H4R 2P1
Canada
Year founded
2023
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
